| Abstract: |
Survival in women with advanced ovarian cancer has markedly improved over the last 30 years through the use of combination platinum and taxane as standard primary chemotherapy, and through progressive improvements in the ability to perform maximal cytoreductive surgery. The goal of surgical cytoreduction has evolved from residual disease ≤1 cm to no visible residual disease, supported by evidence that there is improved survival in women with no remaining visible disease. To achieve this goal, “extended surgery” beyond standard ovarian cancer cytoreduction, including increasingly radical pelvic resection and extensive upper abdominal procedures, are more frequently performed. This chapter details the rationale and procedures required to achieve maximal cytoreduction in most patients, as well as the available evidence for postoperative outcomes after extended surgery. © Springer-Verlag London 2015. |
